OpGen Inc (NASDAQ:OPGN) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price objective of $47.00 for the company and are expecting that the company will post ($2.60) earnings per share for the current quarter, according to Zacks. Zacks has also assigned OpGen an industry rank of 73 out of 256 based on the ratings given to related companies.

Several research analysts have weighed in on OPGN shares. ValuEngine downgraded OpGen from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and issued a $1.50 price target on shares of OpGen in a report on Sunday, May 19th. Zacks Investment Research downgraded OpGen from a “buy” rating to a “hold” rating in a report on Tuesday, June 18th. Finally, Aegis set a $20.00 price target on OpGen and gave the company a “buy” rating in a report on Monday.

OPGN traded up $1.11 during trading on Friday, hitting $7.70. The company’s stock had a trading volume of 12,569 shares, compared to its average volume of 770,155. The firm’s 50 day moving average price is $2.25 and its 200-day moving average price is $1.03. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.89 and a quick ratio of 0.78. The stock has a market cap of $5.55 million, a PE ratio of -0.18 and a beta of 0.77. OpGen has a twelve month low of $4.20 and a twelve month high of $48.20.

A hedge fund recently bought a new stake in OpGen stock. Susquehanna International Group LLP acquired a new position in shares of OpGen Inc (NASDAQ:OPGN) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 71,942 shares of the medical research company’s stock, valued at approximately $28,000. Susquehanna International Group LLP owned about 0.41% of OpGen as of its most recent SEC filing.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Featured Article: What are trading strategies for the 52-week high/low?

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.